Active Pharmaceutical Ingredients CDMO Market Growth & Trends
The global active pharmaceutical ingredients CDMO market size is expected to reach USD 136.1 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 6.7% from 2021 to 2028. Increasing pharmaceutical R&D investment, patent expirations, and rise in demand for generic drugs and biologic innovation are the factors driving the market.
The growth of small molecules, rising Active Pharmaceutical Ingredient (API) complexity, and the need to reduce costs are factors contributing to the rapid expansion of outsourcing services in the pharmaceutical sector. Only a few companies have achieved global reach and scale in the Contract Development and Manufacturing Organization (CDMO) sector, which is still fragmented. Besides, many companies are providing one-stop-shop solutions as an integrated source of APIs and formulations.
However, due to the COVID-19 pandemic, governments worldwide have opted to boycott APIs made in China. Due to government-imposed lockdown limitations in China, 44 firms were declared non-operational during the pandemic. As a consequence, various countries have launched programs to develop their own APIs, and countries across the EU have re-evaluated their healthcare models in order to combat the virus and ensure a steady supply of APIs.
COVID-19 has placed unprecedented expectations on API makers, as evidenced by the substantial increase in demand for medications required to manage critically ill patients on mechanical ventilation. As a result, the sudden need to rapidly increase production has emphasized the need for adaptability for API CDMOs in maintaining drug supply, with some companies proving better able to withstand the pressures of quick scale up than others.
Request a free sample copy or view report summary: Active Pharmaceutical Ingredients CDMO Market Report
Active Pharmaceutical Ingredients CDMO Market Report Highlights
- The traditional active pharmaceutical ingredient dominated the market and accounted for the largest revenue share of 40.5% in 2020
- The innovative drugs segment held 74.6% of the revenue share in 2020. This is largely attributed due to increasing FDA approvals for new molecular entities, and the increased focus on R&D by innovator API companies
- The oncology segment dominated the market and accounted for the largest revenue share of 35.1% in 2020. This is due to the increasing demand for highly active APIs for cancer therapy
- In Asia Pacific, the market is expected to register the fastest growth rate of 8.9% over the forecast period. Due to the extreme rising number of pharmaceutical companies and contract manufacturing organizations in developing countries like India and China, Asia Pacific is likely to overtake Europe and North America in the near future
Access Press Release@ https://www.grandviewresearch.com/press-release/global-active-pharmaceutical-ingredient-cdmo-market
Active Pharmaceutical Ingredients CDMO Market Segmentation
Grand View Research has segmented the global active pharmaceutical ingredients CDMO market based on product, synthesis, drugs, application, workflow, and region:
API CDMO Product Outlook (Revenue, USD Million, 2016 - 2028)
- Traditional Active Pharmaceutical Ingredient
- Highly Potent Active Pharmaceutical Ingredient
- Antibody Drug Conjugate (ADC)
- Others
API CDMO Synthesis Outlook (Revenue, USD Million, 2016 - 2028)
- Synthetic
- Biotech
API CDMO Drugs Outlook (Revenue, USD Million, 2016 - 2028)
- Innovative
- Generics
API CDMO Application Outlook (Revenue, USD Million, 2016 - 2028)
- Oncology
- Hormonal
- Glaucoma
- Cardiovascular
- Diabetes
- Others
API CDMO Workflow Outlook (Revenue, USD Million, 2016 - 2028)
- Clinical
- Commercial
API CDMO Regional Outlook (Revenue, USD Million, 2016 - 2028)
- North America
- US.
- Canada
- Europe
- UK.
- Germany
- France
- Italy
- Spain
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Chile
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
List of Key Players of Active Pharmaceutical Ingredients CDMO Market
- Cambrex
- Recipharm
- Thermo Fisher Pantheon
- Corden Pharma
- Samsung Biologics
- Lonza
- Catalent
- Siegfried
- Piramal Pharma Solutions
- Boehringer Ingelheim
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
No comments:
Post a Comment